BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26260052)

  • 1. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
    Zhang S; Shi W; Chen Y; Xu Z; Zhu J; Zhang T; Huang W; Ni R; Lu C; Zhang X
    Mol Cell Biochem; 2015 Dec; 410(1-2):1-9. PubMed ID: 26260052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
    Wang Z; Wei W; Sun CK; Chua MS; So S
    Liver Int; 2015 Apr; 35(4):1403-15. PubMed ID: 25098386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knocking down the expression of SYF2 inhibits the proliferation of glioma cells.
    Guo J; Yang L; Huang J; Liu X; Qiu X; Tao T; Liu Y; He X; Ban N; Fan S; Sun G
    Med Oncol; 2014 Aug; 31(8):101. PubMed ID: 24985881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma.
    Che Y; Ye F; Xu R; Qing H; Wang X; Yin F; Cui M; Burstein D; Jiang B; Zhang DY
    Am J Pathol; 2012 May; 180(5):1798-807. PubMed ID: 22429965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
    Kim JK; Jung KH; Noh JH; Eun JW; Bae HJ; Xie HJ; Ahn YM; Ryu JC; Park WS; Lee JY; Nam SW
    Int J Oncol; 2009 Dec; 35(6):1257-64. PubMed ID: 19885547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
    Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
    Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of cyclins in hepatocellular carcinoma and its correlation to tumor cell apoptosis].
    Peng SH; Yang JF; Xie PP; Deng H; Li H; Feng DY
    Ai Zheng; 2005 Jun; 24(6):695-8. PubMed ID: 15946481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of p29/SYF2/fSAP29/NTC31 in the progression of NSCLC via modulating cell proliferation.
    Liu Y; Ni T; Xue Q; Lv L; Chen B; Cui X; Cui Y; Wang Y; Mao G; Ji L
    Pathol Res Pract; 2015 Jan; 211(1):36-42. PubMed ID: 25433998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
    Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of vacuolar protein sorting 4B (VPS4B) is associated with accelerated cell proliferation and poor prognosis in human hepatocellular carcinoma.
    Jiang D; Hu B; Wei L; Xiong Y; Wang G; Ni T; Zong C; Ni R; Lu C
    Pathol Res Pract; 2015 Mar; 211(3):240-7. PubMed ID: 25547899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival.
    Liu F; Zhu C; Huang X; Cai J; Wang H; Wang X; He S; Liu C; Yang X; Zhang Y; Zhang T
    Pathol Res Pract; 2014 Dec; 210(12):885-92. PubMed ID: 25169131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin dependent kinase inhibitor p27(kip1) expression and subcellular localization in relation to cell proliferation in hepatocellualr carcinoma.
    Shehata MA; Nosseir HR; Nagy HM; Farouk G
    Egypt J Immunol; 2006; 13(1):115-30. PubMed ID: 17974156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBP-J-interacting and tubulin-associated protein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma by activating the p53-Fbxw7 pathway.
    Wang H; Yang Z; Liu C; Huang S; Wang H; Chen Y; Chen G
    Biochem Biophys Res Commun; 2014 Nov; 454(1):71-7. PubMed ID: 25445601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells.
    Hu C; Liu D; Zhang Y; Lou G; Huang G; Chen B; Shen X; Gao M; Gong W; Zhou P; Dai S; Zeng Y; He F
    Oncogene; 2014 May; 33(22):2888-97. PubMed ID: 23812424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
    Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
    Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
    Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
    Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle.
    Tian Y; Huang C; Zhang H; Ni Q; Han S; Wang D; Han Z; Li X
    Int J Oncol; 2013 Dec; 43(6):2082-90. PubMed ID: 24141559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma.
    Tsao CM; Yan MD; Shih YL; Yu PN; Kuo CC; Lin WC; Li HJ; Lin YW
    Hepatology; 2012 Dec; 56(6):2277-87. PubMed ID: 22767186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.